COA
- Reviews & Citations
No data
The newly identified 2019 novel coronavirus (SARS-CoV-2) has posed a serious threat to human health, and it spreads quickly. It is helpful to develop the Anti SARS-CoV-2 neutralizing antibody titer serologic assay kit to test the protective neutralizing antibody level in serum.
This kit is useful for serologic test for the titer of Anti-SARS-CoV-2 neutralizing antibody in serum/plasma in vitro.
It is for research use only.
Please see Certificate of Analysis for details of reconstitution instruction and specific concentration.
Upon receipt, please store the lyophilized products at-20°C. please store the plate and buffer products at 4-8°C After reconstitution, the stock solution should be kept at -70°C.
It is recommended not to freeze thaw more than 3 times.
This product is stable under storage conditions:
12 months in sealed state;
Used within 3 months after opening.
This assay kit employs a competitive ELISA format and is uniquely suitable for rapid high-throughput detection of the titer of Anti-SARS-CoV-2 neutralizing antibody in serum / plasma. Briefly, we provide you with a biotinylated Human ACE2 protein, a SARS-CoV-2 Spike protein RBD, an Anti-SARS-CoV-2 neutralizing antibody (human IgG1) (as Reference), and Streptavidin-HRP reagent.
a) Coat the plate with SARS-CoV-2 Spike protein RBD.
b) Add 50ul biotinylated human ACE2 to coated plate.
c) Add the reference in kit or your samples from serum or plasma of interest.
d) Add Streptavidin-HRP followed by TMB or other colorimetric HRP substrate.
Finally, the titer of your samples to inhibit Spike protein RBD: ACE2 binding will be determined by comparing OD readings among different experimental groups.
Determination of Anti-SARS-CoV-2 Neutralizing Antibody titer in different concentrations of human serum.
Neutralizing titer of Anti-SARS-CoV-2 Neutralizing Antibody, Human IgG1 (Cat. No. SAD-S35) mesured by Anti-SARS-CoV-2 Neutralizing Antibody Titer Serologic Assay Kit (Cat. No. TAS-K003) in different concentrations of human serum (CV < 30%).
Protocol